CLINICAL ROLE -
Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Levetiracetam Improves Cognitive Function for Some Individuals with Alzheimer Disease
Patients with senile dementia who have silent epileptic activity show improvement when taking this medication.
Read More
Older Women and Younger Men Are More Likely to Have Uncontrolled Hypertension
Study results presented at an American Heart Association conference show that 34% of individuals have high blood pressure.
Extended-Release Narcolepsy Drug Shows Promise in Once-a-Night Dose
Investigators at Stanford Medicine find that 72% of individuals who took the highest dose of ON-SXB were considered much or very much improved.
Study: Antibiotic Regimen Can Treat Round Pneumonia in Pediatric Patients
Treatment of round pneumonia should be followed up with a 2-view chest X-ray weeks later.
IVIG Therapy May Help Treat Drug-Induced Erythroderma
An intravenous immunoglobulin option along with glucocorticoids could be effective in fighting drug-induced erythroderma for patients with AIDS.
New Antibiotics Can Be Useful as Treatment for Community-Acquired Pneumonia
Study shows Lefamulin, omadacycline, ceftaroline, delafloxacin are beneficial in treating community-acquired pneumonia.
FDA Approves Jakafi to Treat Chronic GVHD
The overall response rate of ruxolitinib at week 24 was 49.7% compared with 25.6% for the best available therapy treatment for graft-versus-host-disease.
Moderna COVID-19 Vaccine Remains Effective for 5.3 Months After Second Dose
It demonstrated 93.2% efficacy 14 days afterward and greater than 90% for 4 or more months.
Individuals Aged 50 Years or Older Say Health and Vaccinations Improve Quality of Life
Survey results from Kantar show that people rate these factors more important than an active family life and financial security in terms of well-being.
FDA Approves Opzelura as Treatment for Atopic Dermatitis
In clinical trials, the majority of patients with atopic dermatitis treated with ruxolitinib had clear or almost clear skin.
Study: COVID-19 Vaccines Provide Effective Protection for Individuals With Cancer
These patients had comparable levels of antibodies to individuals without the disease after a 2-dose course of the vaccination.
Pharmacists Can Help Address the Stigma Around Substance Abuse
Thomas Menighan, co-founder of PursueCare and the CEO Emeritus of the American Pharmacists Association, discusses a pharmacists role in National Recovery Month.
AbbVie Announces Application of Skyrizi to FDA for Treatment of Crohn’s Disease
The results of 3 phase 3 trials showed that the drug offered greater proportions of individuals with the condition who met the endpoints of clinical remission and endoscopic response.
Merck Finds Keytruda to Be Effective Treatment for Stage 2 Melanoma
Phase 3 trial results show that the drug reduced the risk of death or reoccurrence by 35% for individuals with high-risk disease compared with the placebo.
Enhertu Treatment for HER2-Positive Breast Cancer Shows Positive Results From Phase 3 Trial
Nearly 94.1% of individuals treated with the drug in the DESTINY-Breast03 study were still alive at the 1-year mark, according to a statement from AstraZeneca.
Study: COVID-19 mRNA Vaccines Rarely Cause Allergic Reactions
Stanford research results show that of nearly 39,000 individuals, just 22 had potential allergic reactions, and all recovered.
AHA: Medication and Surgery Help Reduce High-Blood Pressure Effects
Surgical procedures and weight-loss drugs combat high hypertension in individuals who are obese or overweight, according to the American Heart Association.
FDA Approves Cabometyx to Treat Differentiated Thyroid Cancer
In a phase 3 trial, the medication significantly reduced the risk of disease progression compared with individuals in a placebo group.
EGFR Mutations Help Match Individuals With NSCLC to Treatment
There are 4 essential epidermal growth factor receptor-mutant non-small cell lung cancer subgroups, according to new research results.
Immune Thrombocytopenic Purpura Is Resistant to IVIG Following COVID-19 Vaccine
Study results showed that an individual with the blood disorder did not respond to treatment, including intravenous immunoglobulin, following their second dose of the Pfizer vaccination.
Children With Pre-Existing Conditions Experience More Severe COVID-19
The results of a review by Murdoch Children’s Research Institute finds that pediatric patients who are vaccinated get protection from the long-term effects of the disease.
Economy May Benefit From Making Employees a Vaccine Priority
Investigators at the IMT School for Advanced Studies say that future rollouts should focus on workers, which would help avoid another lockdown.
UVB Radiation May Protect Against Severe COVID-19
Recent study results show that vitamin D may offer protection against critical disease and death.
NIH Gives NYU $470 Million Award to Build COVID-19 RECOVER Initiative
The National Institutes of Health’s studies aim to research the long-term effects of the coronavirus.
FDA Approves First Oral Treatment for EGFR Exon 20+ NSCLC
The FDA approved Exkivity to treat non-small cell lung cancer along with Thermo Fisher Scientific’s Oncomine DX Target Test, which is intended to be a companion diagnostic for the treatment.
COVID-19 Nasal Vaccine Candidate Shows Promise of Development
Investigators said that NanoSTING, can be shipped and stored without the need for freezing for up to 11 months.
PREP Act: Pharmacists Can Administer COVID-19 Therapeutics
Jason Ausili, PharmD, the Chief Clinical Officer of FDS Amplicare, discusses the impact on community pharmacies and patients of the recent announcement by the HHS regarding the amendment to the COVID-19 PREP Act.
Study: Probiotic in Yogurt May Protect Against Antibiotic-Associated Diarrhea
Individuals in a study who received the food with BB-12 probiotic retained beneficial metabolites produced by the microbiota.
Study: Individuals Recovered From COVID-19 Are Protected for Up to 6 Months
New research results show that patients with mild coronavirus produce antibodies that are able neutralize the infection.
Sugemalimab Treatment for Stage 4 NSCLC Prolongs Progression-Free-Survival
The regimen with chemotherapy continues to show longer rates at 9 months compared with 4.9 months for chemotherapy and the placebo.